quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 2, 2026

Uber: From Cash Burner to Cash-Flow Utility

View original at finance.yahoo.com
Uber: From Cash Burner to Cash-Flow Utility This article first appeared on GuruFocus. It has been a fascinating journey watching Uber Technologies evolve from a cash-incinerating startup into what I now consider a dominant, cash-generating utility…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Uber expects to grow Gross Bookings in the mid-teens and EBITDA in the high-30s to 40% range

    80% confidence
  • Waymo vehicles on Uber network in Phoenix and San Francisco are seeing utilization rates significantly higher than human-driven cars

    80% confidence
  • Uber accumulated roughly $32 billion in operating losses prior to mid-2023

    80% confidence
  • Uber is positioning itself to be the essential infrastructure to the autonomous future rather than an inevitable loser in the robotaxi wars

    80% confidence
  • Management describes the gap between Adjusted EBITDA and operating income as due to one-off or non-recurring items, specifically legal reserves, regulatory settlements, and volatility in insurance reserves

    80% confidence
  • Suburban markets are growing 1.5 to 3 times faster than core metro areas

    80% confidence
  • Restaurant delivery represents a $2 trillion Total Addressable Market while general commerce represents a $12 trillion TAM

    80% confidence
  • Uber has scaled its advertising business to over $1 billion in annualized revenue

    80% confidence
  • In Uber's top 10 markets, only about 15% of the adult population uses the service

    80% confidence
  • Only about 20% of Uber's user base utilizes both the Mobility and Delivery platforms, but users who engage with both verticals spend roughly three times more than single-platform users

    80% confidence
  • Instant Retail vertical is running at a $12 billion annualized gross bookings rate

    80% confidence
  • Uber operates the largest mobility and delivery network on the planet with nearly 190 million monthly active platform consumers across 70 countries

    80% confidence
  • Rating Uber stock a Buy with high-conviction accumulation zone between $70 and $80, with 12 to 18 month price target at $110, implying roughly 35-40% upside

    80% confidence

Data points we hold from this source

Uber Technologies · instant retail gross bookings12 billion_USD
Uber Technologies · adjusted ebitda2.3 billion_USD
Uber Technologies · adjusted ebitda growth33 percent
Uber Technologies · advertising revenue1 billion_USD
Uber Technologies · autonomous vehicle partnerships14 partnerships
Uber Technologies · cross platform usage rate20 percent
Uber Technologies · daily trips38 million
Uber Technologies · deferred tax asset release4 billion_USD
Uber Technologies · delivery bookings growth24 percent
Uber Technologies · free cash flow9 billion_USD
Uber Technologies · gross bookings growth21 percent
Uber Technologies · market penetration top 10 markets15 percent
Uber Technologies · monthly active platform consumers190 million
Uber Technologies · net income16 billion_USD
Uber Technologies · operating countries70 countries
Uber Technologies · operating income1.1 billion_USD
Uber Technologies · revenue13.5 billion_USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Uber: From Cash Burner to Cash-Flow Utility — Source | Via News | pt.VIA.NEWS